JP2004196748A - Chitosan-containing antiphlogistic sedative external liquid preparation for skin - Google Patents

Chitosan-containing antiphlogistic sedative external liquid preparation for skin Download PDF

Info

Publication number
JP2004196748A
JP2004196748A JP2002370508A JP2002370508A JP2004196748A JP 2004196748 A JP2004196748 A JP 2004196748A JP 2002370508 A JP2002370508 A JP 2002370508A JP 2002370508 A JP2002370508 A JP 2002370508A JP 2004196748 A JP2004196748 A JP 2004196748A
Authority
JP
Japan
Prior art keywords
chitosan
acid
skin
external liquid
liquid preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002370508A
Other languages
Japanese (ja)
Inventor
Takeo Asanuma
武夫 浅沼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiwa KK
Original Assignee
Daiwa KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiwa KK filed Critical Daiwa KK
Priority to JP2002370508A priority Critical patent/JP2004196748A/en
Publication of JP2004196748A publication Critical patent/JP2004196748A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide a chitosan-containing antiphlogistic sedative external liquid preparation for the skin, not only exhibiting effective activities for ameliorating and preventing aging symptom of the skin, activities for ameliorating rough skin and activities for making the skin beautiful, but also reducing or relieving various kinds of pains such as backache, joint pain and muscle ache. <P>SOLUTION: This chitosan-containing antiphlogistic sedative external liquid preparation for the skin comprises a chitosan having 2,000-1,000,000 molecular weight or 0.2-20.0% aqueous solution of a chitosan derivative. The chitosan-containing antiphlogistic sedative external liquid preparation for the skin preferably contains 0.1-10.0% acid. <P>COPYRIGHT: (C)2004,JPO&NCIPI

Description

【0001】
【発明の属する技術分野】本発明は、腰痛、関節痛、筋肉痛などの各種痛みに対して鎮痛・消炎効果の高い外用組成物に関する。
【0002】
【従来の技術】肩こりや腰痛に対する外用治療には、種々の消炎鎮痛薬が用いられている。
従来からサリチル酸やサリチル酸メチル等のいわゆる刺激型消炎鎮痛薬が汎用されているが、最近では、アントラニル酸系、フェニル酢酸系、インドール系、プロピオン酸系、ピラゾロン系、ベンゾサイアジン系及びスルホンアミド系等の消炎鎮痛薬を配合した外用剤が提供され、これらは経皮吸収型消炎鎮痛薬と言われいる。
【0003】
【発明が解決しようとする課題】本発明の目的は、肩こり及び腰痛に対して治療効果の高い外用組成物を提供することにある。
【0004】
【課題を解決するための手段】本発明者らは、肩こりや腰痛等に対して治療効果を高める外用組成物の開発を目的に研究を重ねた結果、キトサンを配合した液剤が消炎鎮痛効果を発揮することを見出し、本発明を完成するに至った。
すなわち、本発明は下記構成のキトサン含有消炎鎮痛皮膚外用液剤である。
(1)分子量2,000〜1,000,000のキトサン又はキトサン誘導体の0.2〜20.0%水溶液、特に好ましくは0.5〜10.0%水溶液からなることを特徴とするキトサン含有消炎鎮痛皮膚外用液剤。
(2)キトサン含有消炎鎮痛皮膚外用液剤が、酸を0.1〜10.0%含有することを特徴とする前項(1)記載のキトサン含有消炎鎮痛皮膚外用液剤。
(3)キトサン含有消炎鎮痛皮膚外用液剤が、ローション剤であることを特徴とする前項(1)又は(2)に記載のキトサン含有消炎鎮痛皮膚外用液剤。
(4)酸が、クエン酸、酢酸、塩酸、リン酸、マレイン酸及びコハク酸よりなる群より選ばれる1又は2以上であることを特徴とする前項(1)〜(3)のいずれか1項に記載のキトサン含有消炎鎮痛皮膚外用液剤。
【0005】
【発明の実施の形態】本発明の実施の形態を説明する。
従来より、カニやエビの殻に含まれるキチン及びキトサンの抗菌作用はよく知られている。キチンは、甲殻類・昆虫類の外殻のクチクラに含有される成分であり、またキトサンは、キチンを原料とし、加熱したアルカリ溶液でこれを脱アセチル化することにより、工業的に生産されている。
天然高分子であるキトサンの化学構造はセルロースのそれに極めて類似しており、その分子内に存在するアミノ基により強力な分子間結合力を示す。キトサンの用途は多様であり、その脱コレステロール作用、血圧降下作用、免疫強化作用等の生理作用のため、健康食品として用いられている。キトサンは水に不溶であるが、希酸には可溶であり、アミノ基を持つために重金属吸着剤、核酸やエンドトキシン等の酸性物質除去剤として用いられる。また、微生物による分解性が良いため、カチオン系活性汚泥凝集剤としても利用されている。酸性側pHにおいてキトサンを撹拌し溶解させることにより得ることができる。キトサンはそのままでは水に不溶であるが、酸性側pHとすることにより溶解する。製造の手順としては、無論、酸性側pHにおいてキトサンを水溶液と混合することによって製造してもよく、得られる液剤のpHは通常は1〜5、より好ましくは2〜3である。
【0006】
酸性側pHとするには、酸を適宜含有させればよい。ここに用いる酸は、本発明の水性液剤の用途にとって有害なものでない限り特に限定されなく、一般の有機酸や無機酸、例えば、クエン酸、酢酸、塩酸、リン酸、マレイン酸及びコハク酸等を使用してよい。酸、例えばクエン酸は、キトサンを溶解させるのに必要な量を加えればよいが、酸を余分に加えても支障はない。
【0007】
本発明における必須成分であるキトサン及びその誘導体としては、分子量2,000〜1,000,000、特に好ましくは500,000〜100,000のキトサン又はキトサン誘導体が用いられ、そしてその水溶液中の含有量は、0.2〜20.0%、特に好ましくは0.5〜10.0%である。
キトサンの誘導体としては、部分脱アセチル化キチン、N−トリメチル化キトサン等の4級化誘導体等が挙げられる。
また、本発明のキトサン含有消炎鎮痛皮膚外用液剤は酸を含有することが好ましく、その含有量は、好ましくは0.1〜10.0%である。
【0008】
本発明のキトサン含有消炎鎮痛皮膚外用液剤は、基剤成分としての水のほかに、低級アルコール(メタノール、エタノール、変性エタノール、イソプロピルアルコールなど)があり、さらに他の成分、例えば溶解補助剤、界面活性剤、乳化安定剤、ゲル化剤、香料や色素などを添加配合することもできる。
本発明に係るキトサン含有消炎鎮痛皮膚外用液剤は、ローション剤、乳剤、ゲル剤等の液剤型で提供することができる。また、化粧水、乳液、美容液、マッサージ剤、ボディローションなどとしても提供することができる。
【0009】
【実施例】さらに本発明の特徴について、実施例により詳細に説明する。
本発明の実施例の処方を示す。
[実施例1] キトサン含有消炎鎮痛外用液剤「ローション剤」:
(1)エタノール 10.00(重量%)、
(2)酢酸 2.50、
(3)キトサン(分子量10,000)2.0、
(4)精製水 残部、
製法:(1)〜(3)を順次(4)に添加混合し、均一とする。
【0010】
[実施例2] 「ゲル剤」:
(1)ジプロピレングリコール 10.00(重量%)、
(2)カルボキシビニルポリマー 0.10、
(3)水酸化カリウム 0.02、
(4)パラオキシ安息香酸メチル 0.10、
(5)精製水 82.38、
(6)2−ヒドロキシ酪酸 1.50、
(7)酒石酸 2.00、
(8)キトサン(分子量20,000)1.5、
製法:
(5)に(2)を均一に溶解した後、(1)に(4)を溶解して添加し、次いで(3)を加えて増粘させ、(6)〜(8)を混合後添加する。
【0011】
実施例3:「ローション剤」
(1)キトサン(分子量15,000)1.5(重量%)、
(2)アジピン酸ジイソプロピル 2.0、
(3)グリセリン 1.0、
(4)エタノール 15.0、
(5)精製水 残部、
上記成分を攪拌し、均一に溶解させて、ローションタイプの消炎鎮痛皮膚外用液剤を得た。
【0012】
実施例4: 「ローションタイプ」
(1)エタノール 10.00(重量%)、
(2)グリセリン 8.00、
(3)ヒドロキシプロピルメチルセルロース 0.02、
(4)乳酸 1.00、
(5)キトサン 2.5、
(6)ヒアルロン酸ナトリウム 0.01、
(7)アミノ酸混合液 5.00、
(8)パラオキシ安息香酸メチル 0.02、
(9)香料 0.10、
(10)精製水 74.35、
製法:(1)に(8)、(9)を溶解し、(2)〜(7)とともに順次(10)に添加して混合し、均一とする。
【0013】
実施例1に記載のローションタイプのキトサン含有消炎鎮痛皮膚外用液剤をパネラーに適用して、その消炎鎮痛効果について試験した。
その結果を、以下の表1に示す。
【0014】
【表1】

Figure 2004196748
【0015】
その結果から、腰痛、関節痛等の痛みを有していた者20例(No.8は水虫、わきがであって、痛みではない。)中、18例は痛みが治癒し、2例は効果が無かった。したがって、治癒率は90%であった。
【0016】
【発明の効果】本発明のキトサン含有消炎鎮痛皮膚外用液剤を用いれば、有効な皮膚の老化症状の改善,防止作用、肌荒れ改善作用及び美肌作用を奏するばかりでなく、腰痛、関節痛、筋肉痛などの各種痛みを低減・鎮痛することができる。[0001]
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a composition for external use having a high analgesic and anti-inflammatory effect on various pains such as low back pain, joint pain and muscle pain.
[0002]
2. Description of the Related Art Various anti-inflammatory analgesics are used for external treatment for stiff shoulders and back pain.
So-called stimulant anti-inflammatory analgesics such as salicylic acid and methyl salicylate have been used widely, but recently, anthranilic acid, phenylacetic acid, indole, propionic acid, pyrazolone, benzothiazine and sulphonamide are used. There are provided external preparations containing an anti-inflammatory analgesic such as the above, and these are referred to as transdermal anti-inflammatory analgesics.
[0003]
SUMMARY OF THE INVENTION An object of the present invention is to provide a composition for external use having a high therapeutic effect on stiff shoulders and low back pain.
[0004]
Means for Solving the Problems The present inventors have repeatedly studied for the purpose of developing a composition for external use which enhances the therapeutic effect against stiff shoulders and low back pain, and as a result, a liquid formulation containing chitosan has an anti-inflammatory and analgesic effect. The present inventors have found that the present invention is effective, and have completed the present invention.
That is, the present invention is a chitosan-containing antiphlogistic analgesic skin external solution having the following constitution.
(1) Chitosan-containing chitosan or chitosan derivative having a molecular weight of 2,000 to 1,000,000 is characterized by comprising a 0.2 to 20.0% aqueous solution, particularly preferably a 0.5 to 10.0% aqueous solution. Antiphlogistic analgesic skin external solution.
(2) The chitosan-containing anti-inflammatory analgesic skin external solution according to the above (1), wherein the anti-inflammatory analgesic skin external solution contains 0.1 to 10.0% of an acid.
(3) The chitosan-containing anti-inflammatory analgesic skin external liquid according to (1) or (2), wherein the chitosan-containing anti-inflammatory analgesic skin external liquid is a lotion.
(4) The acid according to any one of (1) to (3), wherein the acid is one or more selected from the group consisting of citric acid, acetic acid, hydrochloric acid, phosphoric acid, maleic acid, and succinic acid. Item 4. An external preparation for anti-inflammatory analgesic skin containing chitosan according to item 6.
[0005]
Embodiments of the present invention will be described.
BACKGROUND ART Antibacterial effects of chitin and chitosan contained in crab and shrimp shells have been well known. Chitin is a component contained in the cuticle of the shell of crustaceans and insects, and chitosan is produced industrially by using chitin as a raw material and deacetylating it with a heated alkaline solution. I have.
The chemical structure of chitosan, a natural polymer, is very similar to that of cellulose, and shows stronger intermolecular bonding force due to the amino groups present in the molecule. Chitosan has various uses, and is used as a health food due to its physiological effects such as decholesterolism, blood pressure lowering, and immune enhancement. Chitosan is insoluble in water but soluble in dilute acid and has an amino group, so it is used as a heavy metal adsorbent and as a remover for acidic substances such as nucleic acids and endotoxins. Also, because of its good decomposability by microorganisms, it is also used as a cationic activated sludge flocculant. It can be obtained by stirring and dissolving chitosan at the acidic pH. Chitosan is insoluble in water as it is, but is dissolved by adjusting the pH to the acidic side. As a production procedure, of course, it may be produced by mixing chitosan with an aqueous solution at an acidic pH, and the resulting solution usually has a pH of 1 to 5, more preferably 2 to 3.
[0006]
To make the pH on the acidic side, an acid may be appropriately contained. The acid used here is not particularly limited as long as it is not harmful to the use of the aqueous liquid preparation of the present invention, and general organic acids and inorganic acids such as citric acid, acetic acid, hydrochloric acid, phosphoric acid, maleic acid, and succinic acid. May be used. An acid such as citric acid may be added in an amount necessary for dissolving chitosan, but adding an extra acid does not cause any problem.
[0007]
As chitosan and a derivative thereof, which are essential components in the present invention, chitosan or a chitosan derivative having a molecular weight of 2,000 to 1,000,000, particularly preferably 500,000 to 100,000, is used. The amount is between 0.2 and 20.0%, particularly preferably between 0.5 and 10.0%.
Derivatives of chitosan include quaternized derivatives such as partially deacetylated chitin and N-trimethylated chitosan.
Further, the chitosan-containing antiphlogistic analgesic skin external solution preferably contains an acid, and the content thereof is preferably 0.1 to 10.0%.
[0008]
The chitosan-containing antiphlogistic analgesic skin external liquid preparation of the present invention has a lower alcohol (methanol, ethanol, denatured ethanol, isopropyl alcohol, etc.) in addition to water as a base component, and further contains other components such as a solubilizer, an interface, An activator, an emulsion stabilizer, a gelling agent, a fragrance, a dye, and the like can be added and blended.
The chitosan-containing antiphlogistic analgesic skin external solution according to the present invention can be provided in a liquid form such as a lotion, an emulsion, and a gel. Further, it can be provided as a lotion, an emulsion, a serum, a massage agent, a body lotion and the like.
[0009]
EXAMPLES Further, the features of the present invention will be described in more detail with reference to examples.
1 shows a formulation of an example of the present invention.
[Example 1] Chitosan-containing antiphlogistic analgesic topical solution "lotion":
(1) ethanol 10.00 (% by weight),
(2) acetic acid 2.50,
(3) chitosan (molecular weight 10,000) 2.0,
(4) Remaining purified water,
Production method: (1) to (3) are sequentially added to (4) and mixed to make uniform.
[0010]
Example 2 "Gel":
(1) dipropylene glycol 10.00 (% by weight),
(2) carboxyvinyl polymer 0.10,
(3) potassium hydroxide 0.02,
(4) methyl paraoxybenzoate 0.10,
(5) purified water 82.38,
(6) 2-hydroxybutyric acid 1.50,
(7) tartaric acid 2.00,
(8) Chitosan (molecular weight 20,000) 1.5,
Production method:
After (2) is uniformly dissolved in (5), (4) is dissolved and added to (1), then (3) is added to increase the viscosity, and (6) to (8) are added after mixing. I do.
[0011]
Example 3: "Lotion agent"
(1) chitosan (molecular weight 15,000) 1.5 (% by weight),
(2) diisopropyl adipate 2.0,
(3) glycerin 1.0,
(4) ethanol 15.0,
(5) Remaining purified water,
The above components were stirred and uniformly dissolved to obtain a lotion type antiphlogistic analgesic skin external solution.
[0012]
Example 4: "Lotion type"
(1) ethanol 10.00 (% by weight),
(2) glycerin 8.00,
(3) hydroxypropyl methylcellulose 0.02,
(4) lactic acid 1.00,
(5) Chitosan 2.5,
(6) sodium hyaluronate 0.01,
(7) amino acid mixture 5.00,
(8) methyl paraoxybenzoate 0.02,
(9) Fragrance 0.10,
(10) purified water 74.35,
Production method: (8) and (9) are dissolved in (1), added to (10) sequentially with (2) to (7), mixed and made uniform.
[0013]
The anti-inflammatory analgesic effect of the lotion type chitosan-containing anti-inflammatory analgesic skin external preparation described in Example 1 was applied to panelists and tested for its anti-inflammatory analgesic effect.
The results are shown in Table 1 below.
[0014]
[Table 1]
Figure 2004196748
[0015]
From the results, out of the 20 patients who had pains such as back pain and joint pain (No. 8 was athlete's foot, armpit, not pain), 18 of the patients healed and 2 of them were effective There was no. Therefore, the cure rate was 90%.
[0016]
EFFECT OF THE INVENTION The use of the chitosan-containing anti-inflammatory and analgesic skin external preparation of the present invention not only exerts effective effects of improving and preventing aging of the skin, improving skin roughness, and improving skin beautifulness, but also lower back pain, joint pain, and muscle pain. Various pains such as can be reduced and analgesic.

Claims (4)

分子量2,000〜1,000,000のキトサン又はキトサン誘導体の0.2〜20.0%水溶液からなることを特徴とするキトサン含有消炎鎮痛皮膚外用液剤。A chitosan-containing antiphlogistic analgesic external skin solution comprising a 0.2 to 20.0% aqueous solution of chitosan or a chitosan derivative having a molecular weight of 2,000 to 1,000,000. キトサン含有消炎鎮痛皮膚外用液剤が、酸を0.1〜10.0%含有することを特徴とする請求項1に記載のキトサン含有消炎鎮痛皮膚外用液剤。The chitosan-containing anti-inflammatory analgesic skin external liquid according to claim 1, wherein the anti-inflammatory analgesic skin external liquid contains 0.1% to 10.0% of an acid. キトサン含有消炎鎮痛皮膚外用液剤が、ローション剤であることを特徴とする請求項1又は2に記載のキトサン含有消炎鎮痛皮膚外用液剤。The chitosan-containing anti-inflammatory analgesic skin external liquid according to claim 1 or 2, wherein the chitosan-containing anti-inflammatory analgesic skin external liquid is a lotion. 酸が、クエン酸、酢酸、塩酸、リン酸、マレイン酸及びコハク酸よりなる群より選ばれる1又は2以上であることを特徴とする請求項1〜3のいずれか1項に記載のキトサン含有消炎鎮痛皮膚外用液剤。The chitosan-containing according to any one of claims 1 to 3, wherein the acid is one or more selected from the group consisting of citric acid, acetic acid, hydrochloric acid, phosphoric acid, maleic acid, and succinic acid. Antiphlogistic analgesic skin external preparation.
JP2002370508A 2002-12-20 2002-12-20 Chitosan-containing antiphlogistic sedative external liquid preparation for skin Pending JP2004196748A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2002370508A JP2004196748A (en) 2002-12-20 2002-12-20 Chitosan-containing antiphlogistic sedative external liquid preparation for skin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002370508A JP2004196748A (en) 2002-12-20 2002-12-20 Chitosan-containing antiphlogistic sedative external liquid preparation for skin

Publications (1)

Publication Number Publication Date
JP2004196748A true JP2004196748A (en) 2004-07-15

Family

ID=32766410

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002370508A Pending JP2004196748A (en) 2002-12-20 2002-12-20 Chitosan-containing antiphlogistic sedative external liquid preparation for skin

Country Status (1)

Country Link
JP (1) JP2004196748A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007112968A3 (en) * 2006-04-04 2007-11-15 Marinomed Biotechnologie Gmbh Anti-inflammatory polymer
RU2535141C1 (en) * 2013-04-08 2014-12-10 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Саратовский Государственный Университет Имени Н.Г. Чернышевского" Gel composition of wide spectrum of biological action
CN110339223A (en) * 2019-08-06 2019-10-18 无锡市新吴区新安街道社区卫生服务中心 A kind of spray preparation method for alleviating cervical vertebra disease symptoms

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007112968A3 (en) * 2006-04-04 2007-11-15 Marinomed Biotechnologie Gmbh Anti-inflammatory polymer
RU2535141C1 (en) * 2013-04-08 2014-12-10 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Саратовский Государственный Университет Имени Н.Г. Чернышевского" Gel composition of wide spectrum of biological action
CN110339223A (en) * 2019-08-06 2019-10-18 无锡市新吴区新安街道社区卫生服务中心 A kind of spray preparation method for alleviating cervical vertebra disease symptoms

Similar Documents

Publication Publication Date Title
US10898489B2 (en) Treatment of erectile dysfunction and other indications
US6159977A (en) Therapeutic anti-fungal nail preparation
JPH02503004A (en) Topical metronidazole preparations
JPH0338250B2 (en)
ATE432066T1 (en) MEDICINAL PRODUCTS FOR THE LARGE INTESTINE ADMINISTRATION OF ACTIVE INGREDIENTS
US9289495B2 (en) Systems and methods for treatment of allergies and other indications
JP2016513690A (en) Transdermal delivery of sildenafil and other phosphodiesterase 5 inhibitors
JP2001517621A (en) Non-steroidal anti-inflammatory composition for topical use
RU2358748C2 (en) Local compositions restoring nail structure
JP2004196748A (en) Chitosan-containing antiphlogistic sedative external liquid preparation for skin
JP2008056667A (en) Composition based on salt of hyaluronic acid for treating epithelial lesion
US8367683B2 (en) Composition and method for treatment of warts
JP2012092067A (en) Nonsteroidal anti-inflammatory analgesic agent for external use
JPH09227387A (en) Drug externally using for treatment of atopic dermatitis
JP3723728B2 (en) Skin topical solution
JP4194264B2 (en) Anal skin preparation
US20030077296A1 (en) Sense enhancing topical gel
JP6701978B2 (en) External composition
JPH09110702A (en) Gel preparation containing seawater in deep ocean
RU2210365C1 (en) Agent for scabies treatment
JPS6330404A (en) Dermatic drug for external use
RU2001102894A (en) NECROGEL - A DRUG FOR TREATING INFECTED RAS IN THE AREA OF ANIMAL ANCIENTS AND METHOD FOR ITS OBTAINING
JP2010528065A (en) Anti-inflammatory and analgesic compositions for topical use in the field of animal motor systems
EA200201064A2 (en) Terbinaphine hydrochloride solid medicine form
JPH0624965A (en) Tenidap-containing fomentation

Legal Events

Date Code Title Description
A621 Written request for application examination

Effective date: 20051019

Free format text: JAPANESE INTERMEDIATE CODE: A621

A131 Notification of reasons for refusal

Effective date: 20080521

Free format text: JAPANESE INTERMEDIATE CODE: A131

A02 Decision of refusal

Effective date: 20080924

Free format text: JAPANESE INTERMEDIATE CODE: A02